Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pasithea Therapeutics Corp.

1.11
+0.07006.73%
Post-market: 1.09-0.0197-1.77%19:14 EDT
Volume:23.43K
Turnover:25.45K
Market Cap:1.41M
PE:-0.07
High:1.11
Open:1.03
Low:1.03
Close:1.04
Loading ...

Company Profile

Company Name:
Pasithea Therapeutics Corp.
Exchange:
NASDAQ
Establishment Date:
2020
Employees:
8
Office Location:
1111 Lincoln Road,Suite 500,Miami Beach,Florida,United States
Zip Code:
33139
Fax:
- -
Introduction:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Directors

Name
Position
Lawrence Steinman
Executive Chairman and Co-Founder
Tiago Reis Marques
Chief Executive Officer and Director
Alfred Novak
Director
Emer Leahy
Director
Simon Dumesnil
Director

Shareholders

Name
Position
Tiago Reis Marques
Chief Executive Officer and Director
Daniel Schneiderman
Chief Financial Officer
Graeme Currie
Chief Development Officer
Lawrence Steinman
Executive Chairman and Co-Founder